PMID- 30991815
OWN - NLM
STAT- Publisher
LR  - 20190417
IS  - 1943-572X (Electronic)
IS  - 0003-4894 (Linking)
DP  - 2019 Apr 16
TI  - Early Otorrhea Rates: A Randomized Trial of Ciprofloxacin versus Saline Drops
      after Tympanostomy Tubes.
PG  - 3489419843550
LID - 10.1177/0003489419843550 [doi]
AB  - OBJECTIVE: The objectives of this study are to evaluate incidence, duration, and 
      quality of life (QOL) impact of early tympanostomy tube otorrhea and tube patency
      when comparing topical ciprofloxacin versus normal saline use in the
      perioperative period. METHODS: Overall, 200 patients undergoing tube placement
      between November 19, 2015, and September 12, 2016, were randomized to
      intraoperative plus 5 days of either topical ciprofloxacin or normal saline.
      Parents or caregivers reported the incidence, duration, and QOL impact of early
      otorrhea via 4 weekly surveys. In addition, the patient's otorrhea history and
      tube patency were evaluated at a 4- to 6-week postoperative visit. RESULTS:
      Survey and in-office follow-ups were completed on 128 patients. The overall
      otorrhea incidence was 23.9% for normal saline and 16.7% for ciprofloxacin ( P = 
      .32). The week-by-week otorrhea incidence was not statistically different. The
      percentage of days otorrhea was present, likewise, was not statistically
      different (normal saline 4.5%, ciprofloxacin 2.8%; P = .74). The QOL impact was
      not statistically different (normal saline 1.2, ciprofloxacin 1.5; P = .71). Tube
      patency was not statistically different, with only 1 of 280 ears occluded at
      follow-up. CONCLUSION: We find no difference in the incidence, duration, and QOL 
      impact of early tympanostomy tube otorrhea or tube patency between ciprofloxacin 
      and normal saline. This supports the option to substitute normal saline for
      ciprofloxacin in ears without an active ear infection at the time of tube
      placement, which would reduce both cost and unnecessary antibiotic use. LEVEL OF 
      EVIDENCE: 1b.
FAU - Gabarain, Gabriel
AU  - Gabarain G
AD  - 1 Cleveland Clinic Otolaryngology, Cleveland, Ohio, USA.
FAU - Baird, Rachel
AU  - Baird R
AD  - 2 Cleveland Clinic, Lerner College of Medicine, Cleveland, Ohio, USA.
FAU - Morisada, Megan
AU  - Morisada M
AD  - 2 Cleveland Clinic, Lerner College of Medicine, Cleveland, Ohio, USA.
FAU - Anne, Samantha
AU  - Anne S
AUID- ORCID: https://orcid.org/0000-0002-5719-6206
AD  - 1 Cleveland Clinic Otolaryngology, Cleveland, Ohio, USA.
FAU - Hopkins, Brandon
AU  - Hopkins B
AD  - 1 Cleveland Clinic Otolaryngology, Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
DEP - 20190416
PL  - United States
TA  - Ann Otol Rhinol Laryngol
JT  - The Annals of otology, rhinology, and laryngology
JID - 0407300
OTO - NOTNLM
OT  - chronic otitis media
OT  - conductive hearing loss
OT  - middle ear
OT  - otitis media
OT  - quality of life
OT  - tympanostomy tube
EDAT- 2019/04/18 06:00
MHDA- 2019/04/18 06:00
CRDT- 2019/04/18 06:00
PHST- 2019/04/18 06:00 [entrez]
PHST- 2019/04/18 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
AID - 10.1177/0003489419843550 [doi]
PST - aheadofprint
SO  - Ann Otol Rhinol Laryngol. 2019 Apr 16:3489419843550. doi:
      10.1177/0003489419843550.